Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-A1811 and Adebrelimab in HR+/HER2 Low Early Stage Breast Cancer
NCT07317778Phase 2Not yet recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Feb 2026
- Primary completion
- Oct 2028
- Modality
- Immune Checkpoint Inhibitors, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of trastuzumab rezetecan and adebrelimab in breast cancer (3 arms), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Primary endpoint: Total Pathological Complete Response. Planned start Feb 2026; status: not yet recruiting.
02
Drugs
trastuzumab rezetecanadebrelimab
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT07317778.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07317778.